Ionis Pharmaceuticals IONS Investments - Gross Unrealized Losses

Investments - Gross Unrealized Losses at other companies

Neurocrine BiosciencesNBIX

——

ExelixisEXEL

——

Other financials

Income statement

See full

Revenue$246.1M+87.0%

Gross profit$243.1M+86.8%

Operating income-$117.4M+20.0%

Net income-$92.5M+37.0%

EPS (diluted)-$0.56+39.8%

Balance sheet

See full

Cash & equivalents$173.4M-34.4%

Total debt$691.7M+334%

Total equity$491.4M+3.3%

Total assets$3.4B+22.6%

Cash flow

See full

Operating cash flow-$792.8M-426%

CapEx$21.8M+73.0%

Free cash flow-$814.6M-399%

Valuation

See full

Market cap$12.25B+159%

Enterprise value$12.77B+175%

P/S11.6×+5.0×

Profitability

See full

Gross margin98.4%-0.2pp

Operating margin-33.3%-11.0pp

Net margin-30.9%-10.5pp

FCF margin-77.4%+35.3pp

Returns & leverage

See full

Return on equity-67.6%-20.3pp

Debt / equity1.4×+1.1×

Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's investments - gross unrealized losses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ionis Pharmaceuticals's investments - gross unrealized losses?: Ionis Pharmaceuticals (IONS) reported investments - gross unrealized losses of $1.03B in Q1 2026.
How has Ionis Pharmaceuticals's investments - gross unrealized losses changed year-over-year?: Ionis Pharmaceuticals's investments - gross unrealized losses increased by 28.1% year-over-year, from $806.7M to $1.03B.